Melissa Germain

Assistant Director of Cold Chain Research

Articles by Melissa Germain

  • The Landscape for Pharmaceutical Innovation: Drivers of Cost-Effective Clinical Research

    Saturday, May 01, 2010
    These are remarkable and challenging times for the research-based pharmaceutical and biotechnology industry.
  • Evolving Alliance Management

    Monday, March 01, 2010
    As a leading, global vaccine company, sanofi pasteur is keenly aware of the importance of partnerships and alliances in the successful development of its product pipeline.
  • Strategies for Outsourcing API in Early Development

    Monday, November 01, 2010
    The use of external resources (people, equipment and/or expertise) to facilitate the preparation of API (Active Pharmaceutical Ingredient) or advanced intermediates has become a common practice for most pharmaceutical development organizations.
  • Sentinel Capital Partners Acquires WellSpring Pharmaceutical Corporation

    Tuesday, November 08, 2011
    Sentinel Capital Partners, a private equity firm that invests in promising lower middle market companies, today announced its acquisition of WellSpring Pharmaceutical Corporation, a North American manufacturer and marketer of specialty prescription ...
  • Quintiles Completes Acquisition of Advion BioServices

    Monday, November 07, 2011
    Quintiles’ ability to provide customers with actionable early-stage data to make better development decisions faster has taken a significant step forward with the closing of the previously announced agreement to acquire Advion BioServices, a premier ...
  • Quintiles Agrees to Acquire Premier GLP Bioanalytics Laboratory

    Wednesday, October 26, 2011
    To provide a more comprehensive and efficient global solution for its laboratory customers, Quintiles today announced the signing of a definitive agreement to acquire Advion BioServices, a premier U.S.-based bioanalytical laboratory providing Good ...
  • Relationships with External Partners in Compound Management

    Sunday, January 01, 2012
    This paper outlines how pharmaceutical companies best use external resources to support compound management activities while their internal resources focus on core responsibilities. It also elaborates on compound management workflows in support of ...
  • Forced Degradation to Develop Stability-indicating Methods

    Sunday, January 01, 2012
    Forced Degradation (or stress testing) typically involves exposure of drug substances to heat, heat and humidity and light for solid-state studies. For solution-state studies the drug substance is exposed to a range of pH values. The experimental ...
  • Global Outsourcing

    Sunday, January 01, 2012
    Global outsourcing of pre-clinical studies is an increasingly important aspect of drug discovery and development. In order to extract the most value out of an outsourced pre-clinical project abroad there are several strategic decisions that require ...
  • Late-stage API Development, Manufacturing, and CMO Relations

    Sunday, January 01, 2012
    Late-stage Development and first manufacture represent critical phases for a new API. Outsourcing these complicated tasks adds an additional layer of complexity. Chemistry that has been of secondary importance becomes the highest priority and faces ...
Page